Core Insights - The article discusses the initiation of a Phase III clinical trial for IBI128, a new generation xanthine oxidase inhibitor, aimed at providing an effective and safe treatment option for millions of gout patients in China [1][6]. Disease Background - Gout is one of the fastest-growing metabolic diseases in China, with a hyperuricemia prevalence rate of 17.7% and a gout prevalence rate of 3.2%, affecting over 177 million people, including tens of millions of gout patients [1][6]. - The disease is increasingly prevalent among younger populations, with nearly 60% of patients aged between 18-35 years, and the average onset age dropping to 48.28 years, linked to high-purine diets, sugary beverage consumption, and sedentary lifestyles [1][6]. Mechanism Innovation - IBI128 is a novel non-purine selective xanthine oxidase inhibitor designed to lower blood uric acid levels by inhibiting the key enzyme xanthine oxidase, aiming for higher selectivity and better safety compared to first-generation and second-generation inhibitors [7][8]. - Current treatments face challenges regarding safety and efficacy, including cardiovascular risks and limitations in clinical application due to hypersensitivity reactions and acute kidney injury risks from high uric acid excretion [2][7]. Phase II Data - The Phase II study (CIBI128A201) results presented at the 2025 Asia Pacific League of Associations for Rheumatology Congress showed an 81% target achievement rate for IBI128 at a 100mg dosage, significantly outperforming the 40mg dose of febuxostat [2][8][9]. - This data indicates that IBI128 has the potential to surpass existing standard treatments in uric acid reduction efficacy [9]. Phase III Study Design - The Phase III study is designed as a randomized, double-blind, multi-center trial, enrolling 600 Chinese patients who meet the 2015 ACR/EULAR gout diagnostic criteria, with a treatment period of one year [3][9]. - The primary endpoint is the proportion of patients achieving blood uric acid levels <360 μmol/L at 24 weeks, with long-term observation to validate treatment benefits [3][9]. Strategic Layout - The company is systematically building its portfolio in the gout and hyperuricemia treatment space, aiming to enhance its competitive edge by offering a comprehensive range of treatment options tailored to different disease stages and patient needs [5][10]. - The ongoing advancements of IBI128 from Phase II to the initiation of Phase III trials are seen as a beacon of hope for gout patients, potentially overcoming existing efficacy and safety limitations of current medications [10].

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study Accessibility StatementSkip Navigation SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the xanthine oxidase ...

Core Insights - Innovent Biologics has successfully dosed the first participant in a Phase 1 clinical trial of IBI3011, an anti-IL-1RAP monoclonal antibody aimed at treating gout flares [1][7] Clinical Development - The Phase 1 trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011, with plans to enroll 40 healthy volunteers and 24 patients with gout flares [2] - IBI3011 is the first anti-IL1RAP monoclonal antibody in China, showing significant potential in preclinical models for suppressing gout flares [6][9] Market Need - The number of gout patients in China has exceeded 3 million as of 2019, with rising living standards contributing to this increase [3] - Current treatments for gout flares are limited, with only one IL-1 targeted agent approved in China, indicating a substantial unmet clinical need [4] Mechanism of Action - IL-1RAP acts as a co-receptor that mediates inflammatory signaling pathways, and targeting it can block multiple IL-1 family pathways, potentially leading to rapid control of inflammation and alleviation of gout symptoms [5][9] Future Prospects - Innovent plans to initiate a Phase 3 trial of IBI128 (tigulixostat) for gout patients with hyperuricemia, which has shown strong efficacy in reducing serum uric acid levels in Phase 2 trials [6][7] - The combination of IBI3011 and IBI128 is expected to provide a comprehensive treatment approach for patients with gout and hyperuricemia, enhancing personalized treatment options [6][7] Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, having launched 17 products and currently having multiple assets in clinical trials [10] - The company collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [10]

Core Insights - Innovent Biologics showcased pre-clinical study results for IBI3011 and IBI3034 at the ACR Annual Meeting 2025, highlighting their potential in treating inflammatory and autoimmune diseases [1][2][5]. Group 1: IBI3011 - IBI3011 is a humanized monoclonal antibody that inhibits IL1, IL33, and IL36, effectively alleviating conditions like gout and arthritis in animal models [2][3]. - The drug demonstrates favorable pharmacokinetic properties and safety in monkeys, with a high concentration formulation developed for subcutaneous administration [3][4]. - IBI3011 has received IND approval from China's National Medical Products Administration for acute gouty arthritis, positioning it as a best-in-class therapy with improved response depth and convenience compared to existing treatments [4][7]. Group 2: IBI3034 - IBI3034 is a TACI/BCMA chimeric fusion protein that modulates B lymphocytes and serum immunoglobulin, showing promise for treating B cell-related autoimmune diseases [5][6]. - The drug features half-life extension technology, allowing for a longer dosing interval compared to current therapies, and is well tolerated in monkeys at a dosage of 200 mg/kg [5][6]. - Ongoing IND-enabling studies for IBI3034 aim to further establish its efficacy and safety profile in various autoimmune conditions [6][7]. Group 3: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for oncology, autoimmune, cardiovascular, and metabolic diseases [8][9]. - The company has launched 16 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline and commitment to addressing unmet medical needs [9].